(2024, February 29)
Therefore, GLP-1 medications mimic and enhance the natural physiology of the body
Barber AJ, Gardner TW, Abcouwer SF
Based on the populations studied in clinical trials to date, retatrutide has been investigated primarily in adults living with obesity defined as a body mass index (BMI) of 30 kg/m or above as well as in those who are overweight (BMI 27 kg/m or above) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia
Simplicity of Implementation : The operational mechanism of RAG is relatively straightforward, allowing for easier integration and use
4.4 Long-term safety and off-target effects Emerging reports link GLP-1RAs to rare ocular adverse events, including NAION (Hathaway et al., 2024)